1型糖尿病患者中T细胞和自身抗体对核相关胰岛自身抗原的识别
研究通过系统发现流程鉴定MLH1和NUP50的CD4+ T细胞表位,发现3个DRB1*03:01限制性NUP50表位和4个DRB1*04:01限制性MLH1表位,患者特异性T细胞频率显著高于HLA匹配对照(NUP50 p=0.0012,MLH1 p=0.030),抗体水平升高但高滴度不总与T细胞频率直接相关。
要点
- 鉴定出3个DRB1*03:01限制性NUP50表位和4个DRB1*04:01限制性MLH1表位。
- 1型糖尿病患者NUP50和MLH1特异性T细胞频率显著高于HLA匹配对照。
- MLH1和NUP50抗体水平在1型糖尿病患者中升高,但高滴度不总与T细胞频率直接相关。
核心结论
- T细胞和抗体应答可靶向核相关自身抗原,证实并扩展了既往研究。
- 对并非仅表达于胰岛的蛋白类的疾病相关识别提示疾病过程存在系统性自身免疫成分。
- 关联的抗体识别似乎并非普遍现象,提示对这些自身抗原的体液和细胞应答之间存在微妙关系。
研究设计与样本
- 采用系统发现流程鉴定MLH1和NUP50中的CD4+ T细胞表位。
- 合成源自这些抗原的肽段,检测其与重组DRB1*04:01或DRB1*03:01蛋白的结合能力。
- 通过体外扩增外周血T细胞并使用HLA II类四聚体可视化肽特异性T细胞来评估肽免疫原性。
- 对1型糖尿病患者和HLA匹配对照个体的样本进行直接四聚体染色,以计数MLH1或NUP50反应性CD4+ T细胞并表征其细胞表面表型。
- 使用来自1型糖尿病胰腺器官供者的胰岛衍生T细胞,以细胞因子释放为读出指标表征应答;使用先前发表的ELISA测定匹配血清样本中针对两种抗原的抗体应答。
主要发现
- 发现流程揭示了3个新的DRB1*03:01限制性NUP50表位和4个新的DRB1*04:01限制性MLH1表位,存在于1型糖尿病患者外周血和胰岛浸润物中。
- 针对这些表位的T细胞在糖尿病患者中显著多于HLA单倍型匹配的对照个体(NUP50 p=0.0012,MLH1 p=0.030)。
- 观察到不同程度的抗体应答:MLH1和NUP50抗体水平在1型糖尿病患者中升高,尤其是具有先前报道关联的HLA-DR类型的个体,但高滴度不总是与升高的T细胞频率直接相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: There is a progressive loss of self-tolerance in type 1 diabetes, manifested by the appearance of various autoantibodies. Array-based screening identified antibodies that recognise nucleus-associated proteins in individuals with type 1 diabetes, but the role of these antigens in the disease is poorly understood. Antibodies against MutL homologue 1 (MLH1) and nucleoporin 50 (NUP50) are enriched in DR4-positive and DR3-positive individuals, respectively. Therefore, we sought to investigate CD4+ T cell recognition of these antigens and to assess whether cellular and humoral recognition of these autoantigens are linked. METHODS: We used a systematic discovery process to identify CD4+ T cell epitopes within MLH1 and NUP50. We synthesised peptides derived from these antigens and then measured their ability to bind to recombinant DRB1*04:01 or DRB1*03:01 protein, our two HLA class II types of interest. We assessed peptide immunogenicity by expanding peripheral blood T cells in vitro and visualising peptide-specific T cells using HLA class II tetramers. We then performed direct tetramer staining of samples from individuals with type 1 diabetes and HLA-matched control individuals to enumerate MLH1- or NUP50-reactive CD4+ T cells and characterise their cell surface phenotype. Responses were also characterised using islet-derived T cells from pancreatic organ donors with type 1 diabetes using cytokine release as a readout. Antibody responses against both antigens were measured in matched serum samples using a previously published ELISA assay. RESULTS: Our discovery process revealed three novel DRB1*03:01-restricted NUP50 epitopes and four novel DRB1*04:01-restricted MLH1 epitopes that are present within the peripheral blood of individuals with type 1 diabetes and among pancreatic islet infiltrates. T cells specific for these epitopes were significantly more frequent in individuals with diabetes than in HLA haplotype-matched control individuals (p=0.0012 and 0.030 for NUP50 and MLH1, respectively). Variable levels of antibody responses were observed: elevated levels of MLH1 and NUP50 antibodies were present in individuals with type 1 diabetes, especially those with the HLA-DR types with previously reported associations, but high titres did not always directly correlate with elevated T cell frequency. CONCLUSIONS/INTERPRETATION: The observation that T cell and antibody responses can target nucleus-associated self-antigens confirms and extends previously published studies. Disease-associated recognition of a class of proteins that are not exclusively expressed in pancreatic islets implies a systemic autoimmune component to the disease process. Linked antibody recognition does not appear to be a general phenomenon, suggesting a subtle relationship between humoral and cellular responses to these self-antigens.
引用
- Guyer P, Seminova K, Lugar M, et al. T cell and autoantibody recognition of nucleus-associated islet autoantigens in individuals with type 1 diabetes. Diabetologia. 2025. PMID: 40490584. doi:10.1007/s00125-025-06458-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。